May 10, 2019
May 13, 2020
This is a Single Patient Investigational New Drug (IND) to golimumab subcutaneous (SC) for the treatment of recently diagnosed Stage 3 type-1 diabetes mellitus (T1D) in children and young adults. The main purpose of a single patient IND is to provide treatment to participants with serious/life-threatening diseases or conditions prior to marketing authorization.
Contact: Study Contact 1-800-JANSSEN (1-800-526-7736) Janssenmedinfo@its.jnj.com
United States, California
Rady Children's Hospital
Janssen Research & Development, LLC
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC